KT Tape acquired by private equity firm Palladin Consumer Retail Partners
BOSTON — Private equity firm Palladin Consumer Retail Partners on Thursday announced the acquisition of KT Health, a producer of kinesiology tape and related sports medicine products in the retail market. KT Tape, the company’s flagship product, is used by professional and recreational athletes to prevent injury, reduce pain, promote recovery and maximize comfort.
“We are excited to join forces with the Palladin team, who have tremendous experience in growing consumer brands," stated John Mackay, KT Health CEO. "Their support, expertise and involvement will be instrumental in capitalizing on the significant growth opportunities ahead. We also look forward to working with our great retail partners and loyal customers, as we expand the reach of KT Tape and introduce other related products to benefit athletes worldwide.”
KT Tape is sold in 22,000 retail doors in the United States in sporting goods, food, drug and mass retail channels, as well as through clinicians, online retailers and the company’s own e-commerce site, KTTape.com, the company stated.
KT Health, based in Lindon, Utah, was formed in 2008 with the intent of empowering everyday athletes to prevent injury, recover faster and play harder. The company will continue to be led by its founders, Mackay, Jim Jenson and Ryan Dewey. The founders and other shareholders will partner with Palladin by reinvesting a significant portion of their equity. Palladin’s support will enable KT Health to expand its market presence, product range and opportunities in the sports medicine category.
Terms of the transaction were not disclosed.
Study: Potential therapeutic role for aspirin in inhibiting cancerous vestibular schwannoma growth
BOSTON — Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated that aspirin intake correlates with halted growth of vestibular schwannomas, also known as acoustic neuromas, a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.
Motivated by experiments in the Molecular Neurotology Laboratory at Mass. Eye and Ear involving human tumor specimens, the researchers performed a retrospective analysis of more than 600 people diagnosed with vestibular schwannoma at Mass. Eye and Ear. Their research suggests the potential therapeutic role of aspirin in inhibiting tumor growth and motivates a clinical prospective study to assess efficacy of this well-tolerated anti-inflammatory medication in preventing growth of these intracranial tumors.
"Currently, there are no FDA-approved drug therapies to treat these tumors, which are the most common tumors of the cerebellopontine angle and the fourth most common intracranial tumors," explained Konstantina Stankovic, Mass. Eye and Ear clinican-researcher and assistant professor of otology andlaryngology, Harvard Medical School, who led the study. "Current options for management of growing vestibular schwannomas include surgery — via craniotomy — or radiation therapy, both of which are associated with potentially serious complications."
The findings, which are described in the February issue of the journal Otology and Neurotology, were based on a retrospective series of 689 people, 347 of whom were followed with multiple magnetic resonance imaging MRI scans. The main outcome measures were patient use of aspirin and rate of vestibular schwannoma growth measured by changes in the largest tumor dimension as noted on serial MRIs.
"Our results suggest a potential therapeutic role of aspirin in inhibiting vestibular schwannoma growth," Stankovic said.
McNeil promotes OTC safety with new website
FORT WASHINGTON, Pa. — McNeil Consumer Healthcare on Thursday launched an enhanced consumer education website called GetReliefResponsibly.com to promote safety in using OTC medicines to help kick a cold.
Each year, an estimated 7-in-10 Americans turn to OTC medicines to treat their cold and flu symptoms, McNeil reported. Many of these medicines contain acetaminophen, a common pain reliever/fever reducer that patients and consumers rely on to provide relief from cold and flu symptoms, such as headache, fever, sore throat and body pains. Acetaminophen is the active ingredient in Tylenol and also can be found in more than 600 OTC and prescription medications, such as NyQuil, Theraflu, Percocet and Vicodin.
Particularly during cold-flu season, when consumers are seeking relief, they may reach for more than one medication to treat their symptoms. It is important that consumers are aware of the ingredients in their medications and that they read and follow their medicine labels to help prevent accidentally taking more than the maximum daily dose of acetaminophen, McNeil noted.
"Acetaminophen is safe when used as directed, but taking too much of it can harm your liver," stated Edwin Kuffner, VP medical affairs and clinical research at McNeil. "Some people may accidentally take more than the total daily dose of acetaminophen because they do not realize they are taking multiple products containing acetaminophen, or because they may not read and follow the label."
At the enhanced GetReliefResponsibly.com website, consumers can try out the new interactive medicine checker and see if the OTC or prescription medicines they are taking contain acetaminophen. The site features several videos about general acetaminophen safety, an illustrated guide on how to read medicine labels and proper acetaminophen dosage for adults and children. The site also features tips on how to keep medicines safely out of the reach of children and a companion diagram showing specific locations within the home to be extra cautious about — areas where medicines might commonly be left within the reach of children.
"Through our enhanced website and other education efforts, we want to help patients and consumers use our medicines safely and appropriately," Kuffner said. "The tools and information available on the site are easy to use, and can help families ensure they get relief safely this cold-flu season."